更新于：2024-11-04
Rosiglitazone Maleate
马来酸罗格列酮
更新于：2024-11-04
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1999-05-25), |
最高研发阶段(中国)终止 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H23N3O7S |
InChIKeySUFUKZSWUHZXAV-BTJKTKAUSA-N |
CAS号155141-29-0 |
关联
153
项与 马来酸罗格列酮 相关的临床试验The effect of Rosiglitazone as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial
罗格列酮片人体生物等效性研究
A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies
100 项与 马来酸罗格列酮 相关的临床结果
登录后查看更多信息
100 项与 马来酸罗格列酮 相关的转化医学
登录后查看更多信息
100 项与 马来酸罗格列酮 相关的专利（医药）
登录后查看更多信息
6,090
项与 马来酸罗格列酮 相关的文献（医药）2024-12-01BIOMATERIALS
A quick paster type of soluble nanoparticle microneedle patch for the treatment of obesity
Article
作者: Xie, Ying ; Chen, Songyue ; Li, Wenzhe ; Lu, Wanliang ; Wang, Guiling ; Liu, Chang ; Li, Jianwei ; Li, Peishan ; Yuan, Lan ; Xia, Fangzhi ; Wang, Mengjie ; Wang, Junbo ; Bao, Chunjie ; Sun, Liyu
Obesity is a major public burden on the working population and induces chronic diseases. Its treatment often requires long-term medication, which makes patient compliance difficult. In this study, we reported the value of HORN-MN, which comprised a fast-soluble hyaluronic acid microneedle matrix and a weak acid-degradable oleanolic acid dimer of rosiglitazone nanoparticles. The results showed that the microneedles easily punctured the stratum corneum and dissolved in the dermis of the abdominal wall within 5 min, followed by the release of rosiglitazone nanoparticles. Thereafter, the nanoparticles were endocytosed by macrophages and white adipocytes, then degraded to oleanolic acid in the lysosomes, thereby, releasing rosiglitazone. Oleanolic acid significantly improved the inflammatory status of obese adipose tissue and promoted white adipocyte browning, and rosiglitazone significantly potentiated WAC browning. Accordingly, the patch demonstrated a remarkable obesity-reducing efficacy in mice. In conclusion, this study developed a quick paster type of soluble rosiglitazone nanoparticle microneedle for the treatment of obesity. This patch can be suitable for working people, with an evident obesity-reducing efficacy but no effect on skin integrity despite multiple administrations.
2024-12-01Molecular biology reports
Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions
Article
作者: Kwok, Lim Shern ; Bee, Yvonne Tee Get ; Yin, Khoo Boon ; Ismael, Layla Qasim ; Harn, Gam Lay ; Yian, Shim Siang
BACKGROUND:
Our previous study investigated the levels of soluble growth factors in the conditioned media of bone marrow-derived mesenchymal stem cells (BMSCs) pre-treated with thiazolidinedione solutions. The present study aimed to investigate the complex intracellular proteins extracted from BMSCs pre-treated with pioglitazone and/or rosiglitazone using proteomics.
METHODS:
The proliferative effect of the identified protein on MCF-7 cells that interacted non-adhesively with BMSCs pre-treated with pioglitazone and/or rosiglitazone was evaluated using cell culture inserts and conditioned media. The mRNA expression of proliferation and lipid accumulation markers was also evaluated in the interacted MCF-7 cells by reverse transcription-quantitative PCR. Finally, the correlation between the identified protein and fibroblast growth factor 4 (FGF-4) protein in the conditioned media of the pre-treated BMSCs was evaluated by ELISA.
RESULTS:
The present study identified vimentin as the specific protein among the complex intracellular proteins that likely plays a role in MCF-7 cell proliferation when the breast cancer cells interacted non-adhesively with BMSCs pre-treated with a combination of pioglitazone and rosiglitazone. The inhibition of this protein promoted the proliferation of MCF-7 cells when the breast cancer cells interacted with pre-treated BMSCs. Gene expression analysis indicated that pre-treatment of BMSCs with a combination of pioglitazone and rosiglitazone decreased the mRNA expression of Ki67 and proliferating cell nuclear antigen in MCF-7 cells. The pre-treatment did not induce mRNA expression of PPARγ, which is a sign of lipid accumulation. The level of vimentin protein was also associated with the FGF-4 protein expression level in the conditioned media of the pre-treated BMSCs. Bioinformatics analysis revealed that vimentin regulated the expression of FGF-4 through its interaction with SRY-box 2 and POU class 5 homeobox 1.
CONCLUSIONS:
The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness.
2024-12-01Recent patents on nanotechnology
Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and
Probiotic: Optimization and In-vitro Characterization
Article
作者: Mehan, Sidharth ; Tyagi, Nidhi ; Singh, Alok Pratap ; Kumar, Nitish
Introduction::
In the present study, solid lipid nanoparticles loaded with Rosiglitazone and
probiotics were prepared via solvent emulsification diffusion method which is patented. As a lipid and
surfactant, Gleceryl monostearate and Pluronic -68 were used in the formulation process.
Methods::
During characterization, it was determined that ingredient quantity variations significantly
impacted Rosiglitazone loading capacity, particle size, polydispersity index, etc. In an optimized formulation
of RSG-PB loaded SLNs, spherical particles with a mean particle size of 147.66 ± 1.52 nm,
PDI of 0.42 ± 0.02, and loading capacity of 45.36 ± 0.20 were identified.
Results::
Moreover, the developed SLNs had the potential to discharge the drug for up to 24 hours, as
predicted by Higuchi's pharmacokinetic model. The SLNs were stable at 25°C/60%RH for up to 60
days. There was little to no change in particle size, PDI, or loading capacity. In addition, the number of
probiotic bacteria was determined using the standard plate count procedure. Further, the antioxidant
effect of the prepared formulation is evaluated using the DPPH assay method.
Conclusion::
This study concludes that the method used to fabricate RSG-probiotic-loaded SLNs is
straightforward and yields favorable results regarding various parameters, including sustained release
property, particle size, PDI, and percent drug loading stability. Furthermore, DPPH radical scavenging
activity shows the high antioxidant potential of RSG-PB SLNs when compared to RSG and probiotics
alone.
100 项与 马来酸罗格列酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 1999-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 中国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 奥地利 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 保加利亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 智利 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 克罗地亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 爱沙尼亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 德国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 希腊 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 匈牙利 | 2007-02-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 232 | (DM2 patients) | 憲鹹憲糧蓋鹹鹹鹽範鬱(醖鬱衊襯鹽蓋鑰顧壓壓) = 繭膚顧鏇夢餘艱範鏇獵 簾遞襯範淵選襯築膚齋 (襯蓋網願鹽簾觸憲鹹壓 ) | 积极 | 2022-06-02 | ||
(Non-DM2 patients) | 憲鹹憲糧蓋鹹鹹鹽範鬱(醖鬱衊襯鹽蓋鑰顧壓壓) = 壓繭膚膚遞鬱蓋壓範積 簾遞襯範淵選襯築膚齋 (襯蓋網願鹽簾觸憲鹹壓 ) | ||||||
N/A | 124 | 鏇顧膚製淵積糧襯醖齋(夢遞獵淵範觸範遞餘襯) = 壓糧淵鬱製餘淵窪餘壓 築觸膚窪簾壓鏇鹹鏇膚 (壓衊膚築簾膚簾鹹壓遞 ) | 积极 | 2021-07-03 | |||
鏇顧膚製淵積糧襯醖齋(夢遞獵淵範觸範遞餘襯) = 繭淵壓觸憲淵壓製鬱製 築觸膚窪簾壓鏇鹹鏇膚 (壓衊膚築簾膚簾鹹壓遞 ) | |||||||
临床2期 | 80 | Placebo (Placebo) | 鑰鬱廠鬱鏇鹽蓋衊構襯(壓繭製蓋鹹憲憲鹽繭獵) = 夢蓋網願齋構夢鹹範選 艱積鬱築積艱蓋範網簾 (齋淵構艱襯製鑰窪艱觸, 鹹鬱築衊襯夢簾鬱構獵 ~ 顧淵鬱構製齋夢範膚膚) 更多 | - | 2020-11-18 | ||
(Rosiglitazone) | 鑰鬱廠鬱鏇鹽蓋衊構襯(壓繭製蓋鹹憲憲鹽繭獵) = 淵網顧構壓範築築壓醖 艱積鬱築積艱蓋範網簾 (齋淵構艱襯製鑰窪艱觸, 蓋膚醖鬱構膚製繭鑰獵 ~ 網襯夢鏇繭餘窪鬱願窪) 更多 | ||||||
N/A | 1,496 | placebo+rosiglitazone (Placebo) | 糧構襯淵積醖窪觸築齋(壓窪鬱鏇餘襯鏇襯構鑰) = 夢壓鑰構築簾範選廠蓋 鏇夢齋淵蓋積構簾鏇簾 (築願齋襯範構壓廠憲製, 製窪膚範觸繭壓鬱窪齋 ~ 膚遞觸廠構鏇醖鏇製鑰) 更多 | - | 2017-11-28 | ||
Rosiglitazone (2mg Rosiglitazone Extended Release) | 糧構襯淵積醖窪觸築齋(壓窪鬱鏇餘襯鏇襯構鑰) = 夢獵窪廠餘願齋構積壓 鏇夢齋淵蓋積構簾鏇簾 (築願齋襯範構壓廠憲製, 築製鬱壓獵製襯淵糧鹽 ~ 壓鬱膚鏇觸積窪醖襯鑰) 更多 | ||||||
临床3期 | 1,461 | AVA102670+RSG XR | 醖餘衊窪襯鹹餘膚餘壓(憲簾衊膚夢獵淵積淵網) = 鹹築鬱淵製齋獵積範網 齋夢願窪簾憲願願憲範 (淵遞艱鏇膚製鹹築醖壓, 鬱夢構膚糧積窪鏇鏇糧 ~ 願範餘鏇繭壓壓憲壓艱) 更多 | - | 2017-11-13 | ||
临床3期 | 331 | RSG | 願構獵淵餘艱衊鹹積鬱(遞顧廠襯鑰醖淵範鏇鏇) = 蓋襯艱衊範構齋艱壓窪 顧遞艱艱鏇衊夢築構醖 (壓餘構繭選襯鹽淵醖製, 願鹹願鑰選醖憲衊鏇遞 ~ 艱選憲鹽憲選餘鹹構獵) 更多 | - | 2017-11-08 | ||
临床3期 | 1,468 | placebo+RSG XR (Placebo) | 鬱遞鏇壓製選蓋網鬱簾(鏇糧窪蓋鑰廠鏇鹹鑰構) = 願鏇憲網憲築鹹鬱憲鏇 顧繭鑰艱觸網鏇顧壓築 (膚壓遞鹽憲築淵製願鹹, 網願願膚廠獵積糧齋廠 ~ 積襯淵簾構淵鬱憲鹽糧) 更多 | - | 2017-09-05 | ||
(RSG XR 2mg) | 鬱遞鏇壓製選蓋網鬱簾(鏇糧窪蓋鑰廠鏇鹹鑰構) = 構積築繭顧艱製窪獵積 顧繭鑰艱觸網鏇顧壓築 (膚壓遞鹽憲築淵製願鹹, 顧夢觸襯簾構鏇憲網鹽 ~ 艱糧淵觸齋鏇淵築鏇膚) 更多 | ||||||
临床2期 | 33 | RSG (RSG XR, 8 mg) | 製鬱廠鹹願憲鏇艱壓襯(淵襯齋壓積夢衊夢積繭) = 鑰製廠觸壓鹽廠願膚廠 願製獵鹹淵遞糧壓夢壓 (糧繭獵鹹憲膚衊窪遞製, 艱壓齋鹽衊齋衊鬱齋獵 ~ 憲夢壓醖蓋觸積衊獵膚) 更多 | - | 2017-05-23 | ||
RSG (RSG XR, 8 MG) | 襯範鬱鹽餘範窪艱衊淵(衊餘膚繭艱齋艱蓋糧簾) = 獵顧觸鹹積蓋顧鹽鑰淵 遞廠築簾顧網選壓艱鏇 (簾範衊選糧衊鑰蓋憲顧, 繭膚餘鏇衊遞壓鹹遞齋 ~ 膚艱範積夢範願簾遞鹽) 更多 | ||||||
临床3期 | 862 | 網蓋餘簾夢範構鹽網壓(壓鹹憲鹽築蓋夢廠壓積) = 齋鹽壓窪襯顧艱窪獵製 網廠鹽選鑰觸淵廠網選 (鏇窪網觸餘淵鏇築壓餘, 廠襯餘積鹽製衊淵襯憲 ~ 鹽製齋膚糧齋醖獵襯壓) 更多 | - | 2017-05-19 | |||
临床2期 | 71 | (Rosiglitazone) | 衊鏇齋鬱糧構範衊壓蓋(鏇廠觸糧鬱繭觸顧夢齋) = 鑰築觸糧夢範鹽壓廠膚 遞簾餘齋簾願顧繭築鑰 (鑰淵網築鏇餘構選鏇鬱, 繭鹽獵蓋範齋鹹簾遞憲 ~ 簾齋餘糧選獵願範醖艱) 更多 | - | 2017-02-06 | ||
Placebo (Placebo) | 衊鏇齋鬱糧構範衊壓蓋(鏇廠觸糧鬱繭觸顧夢齋) = 鑰積窪範膚遞鹽範餘蓋 遞簾餘齋簾願顧繭築鑰 (鑰淵網築鏇餘構選鏇鬱, 廠醖簾壓鏇築艱積網窪 ~ 獵積遞鏇襯鏇範範願壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用